Search

EMPERIAL-heart-failure-toplineresults

Update on the EMPERIAL-Reduced and EMPERIAL-Preserved studies, which assess exercise ability in adults with chronic heart failure with reduced and preserved ejection fraction

FDA- HFpEF-breakthrough-designation-EMPEROR-preserved

U.S. FDA issues Breakthrough Therapy Designation for the treatment of adults with heart failure with preserved ejection fraction

Transboundary animal diseases and veterinary preparedness

What are transboundary animal diseases (TADs)? Bluetongue virus, foot-and-mouth disease and avian influenza are pathogens belonging to this group.

Boehringer Ingelheim Second Transforming Science Day

World-renowned top scientists and companies in R&D take the stage at Boehringer Ingelheim’s second Transforming Science Day

Health, Safety & Environment

Suppliers shall provide a safe and healthy working environment and shall operate environmentally responsible and sustainable.

The power of our people

Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.

Collaboration Boehringer Ingelheim Veeva technology

Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster

MORE GREEN: Reducing emissions throughout the supply chain

How Thermo Fisher is contributing to the decarbonization of Boehringer Ingelheim’s supply chain by reducing their own emissions

emperor-preserved-chmp-positive-opinion

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

Laura loves her diverse career

Laura loves her diverse career at Boehringer Ingelheim. For more talent insights, visit our Careers Page.

COVID-19 Protecting Our Employees

Boehringer Ingelheim has taken precautions to protect the health of employees and mitigate the risk of COVID-19 affecting our organization.

European Metacam® indication expanded to guinea pigs

Boehringer Ingelheim adds a new species to its Metacam® brand in Europe, expanding the indications of this widely-used medicine to guinea pigs.

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.

Announcement for Imagine - our new sustainability story hub

Discover Imagine, our sustainability story hub, showcasing how we drive health equity and advance sustainable healthcare solutions for a better future

Joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Boehringer Ingelheim announces appointments

FDA approves Jardiance treatment chronic kidney disease

U.S. FDA approves Jardiance® for treatment of adults with chronic kidney disease

Is artificial intelligence the future of farming?

Lead with Pride – for the Benefit of All.

How Inclusive Leadership advocates for Acceptance and creating a Sense of Belonging

Europe needs a vibrant research eco-system

At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.

Boehringer Ingelheim attends WVPAC 2019

Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress